FAITH trial: Feasibility and safety of anlotinib plus benmelstobart in patients with previously immunotherapy treated intermediate-to-advanced hepatocellular carcinoma—Amulticenter, single arm, prospective phase Ⅱ trial.Ying-Hao Shen, Hui‐Chuan Sun, Zhiwei Li et al.|Journal of Clinical Oncology|2025Cited by 1